Figure 3.

Number of deaths and 30-day all-cause mortality of a total of 116,541 patients from the 3 different organizations with regard to their Charlson comorbidity score and SLUScore. Both scoring systems independently portended decreased 30-day survival in association with progressively greater scores. With nearly 90% of patients having a Charlson score ≤2, overall more patients’ decreased survival occurred in association with a progressively greater SLUScore than a progressively greater Charlson score.¹⁵